ArticleCancers2024
A High-Throughput Immune-Oncology Screen Identifies Immunostimulatory Properties of Cytotoxic Chemotherapy Agents in TNBC.
Kennady K Bullock, Thomas Hasaka, Emily Days, Joshua A Bauer, Patricia A Ward, Ann Richmond
Abstract read
In one paragraphArticle in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Kennady K BullockDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0002-9773-3512 Thomas HasakaVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA.
Emily DaysVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA.
Joshua A BauerVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA.ORCID 0000-0002-8019-900X Patricia A WardDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Ann RichmondDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0002-9580-900X Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MCancer Pharmacologist and HTS ScientistR50CA211206 · NCI · VANDERBILT UNIVERSITY · PI Joshua A. Bauer · 2016 to 2026
$1.8MOptimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathwayR01CA243326 · NCI · VANDERBILT UNIVERSITY · PI RICHMOND, ANN, YAN, CHI · 2020 to 2024
$1.8MIntegrated ImageXpress Micro Confocal High Content Screening SystemS10OD028719 · OD · VANDERBILT UNIVERSITY · PI BAUER, JOSHUA A. · 2021 to 2021
$799kAutomated Compound Storage and Retrieval SystemS10OD028715 · OD · VANDERBILT UNIVERSITY · PI BAUER, JOSHUA A. · 2022 to 2022
$741kEnhancing triple negative breast cancer response to immune checkpoint inhibitor therapy via targeted therapiesF31CA271790 · NCI · VANDERBILT UNIVERSITY · PI BULLOCK, KENNADY · 2023 to 2024
$40kNCI NIH HHS F31 CA271790NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA243326NCI NIH HHS R50 CA211206NIH HHS 1S10CA028719-05A1NIH HHS S10 OD028715NIH HHS S10 OD028719
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
breast cancerCD8+ T-cellscytotoxic chemotherapyimmune response
Identifiers
PMID39682260
PMCPMC11639798
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390